Fennec Pharmaceuticals Inc. (FRX.TO)
| Previous Close | 11.00 |
| Open | 11.18 |
| Bid | 10.99 x 0 |
| Ask | 11.21 x 0 |
| Day's Range | 11.00 - 11.18 |
| 52 Week Range | 7.28 - 12.42 |
| Volume | 338 |
| Avg. Volume | 861 |
| Market Cap | 289.457M |
| Beta (5Y Monthly) | -0.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.87 |
| Earnings Date | Nov. 15, 2021 - Nov. 19, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
4 Breakout Stocks for Impressive Returns
SB, VTSI, FENC and APYX qualified the screen for breakout stocks for today.
- GlobeNewswire
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that management will participate in three upcoming virtual investor conferences, including H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13
- GlobeNewswire
Fennec Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update
~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~ ~ If Approved by the FDA, PEDMARK™ Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ Company Has Approximately $27 Million in Cash and Cash Equivalents ~ RESEARCH TRIANGLE PARK, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique for
